How a Milk-Derived Peptide Kills Candida Fungal Infections
LfcinB15, a lactoferricin-derived peptide, kills Candida albicans through multiple mechanisms including membrane disruption, reactive oxygen species generation, and mitochondrial dysfunction.
Quick Facts
What This Study Found
LfcinB15 kills Candida albicans through at least three mechanisms: membrane disruption, ROS generation, and mitochondrial dysfunction, while activating Hog1 and Mkc1 stress-response kinases.
Key Numbers
Active vs planktonic + biofilm C. albicans + clinical isolates + non-albicans; membrane disruption; ROS generation; mitochondrial dysfunction; Hog1 + Mkc1 activated
How They Did This
In vitro susceptibility testing against planktonic and biofilm cells. Fluorescence microscopy for peptide localization. Membrane integrity assays, ROS detection, mitochondrial function assessment, and Western blot for MAPK activation in C. albicans.
Why This Research Matters
Candida infections are increasingly resistant to conventional antifungal drugs. Understanding how antimicrobial peptides kill fungi through multiple simultaneous mechanisms could help develop new antifungal strategies that are harder for pathogens to resist.
The Bigger Picture
Antifungal resistance is a growing concern, with the WHO listing Candida species among priority fungal pathogens. Antimicrobial peptides with multiple killing mechanisms are less likely to encounter resistance than single-target drugs, making them promising alternatives.
What This Study Doesn't Tell Us
In vitro study only. No animal infection model data. Peptide stability and efficacy in vivo not tested. Specific MIC values not reported in abstract.
Questions This Raises
- ?Would LfcinB15 be effective in animal models of Candida infection?
- ?Could resistance develop against multi-mechanism peptides like LfcinB15?
- ?How does LfcinB15 compare to conventional antifungals in biofilm eradication?
Trust & Context
- Key Stat:
- Triple killing mechanism Membrane disruption, ROS generation, and mitochondrial dysfunction work together against Candida
- Evidence Grade:
- Thorough in vitro mechanistic study with multiple complementary assays. Provides strong mechanistic evidence but lacks in vivo validation.
- Study Age:
- Published in 2021, contributing to understanding of antimicrobial peptide mechanisms against priority fungal pathogens.
- Original Title:
- Antimicrobial Activity of the Peptide LfcinB15 against Candida albicans.
- Published In:
- Journal of fungi (Basel, Switzerland), 7(7) (2021)
- Authors:
- Chang, Che-Kang, Kao, Mou-Chieh, Lan, Chung-Yu
- Database ID:
- RPEP-05308
Evidence Hierarchy
Frequently Asked Questions
What is LfcinB15 and where does it come from?
LfcinB15 is a peptide derived from bovine lactoferricin, which itself comes from lactoferrin — a protein found in cow's milk. It has been designed as a shorter, more potent version of the natural antimicrobial peptide.
Why use peptides instead of standard antifungal drugs?
Standard antifungal drugs typically attack one target, making it easier for fungi to develop resistance. LfcinB15 kills Candida through at least three different mechanisms simultaneously — disrupting the cell membrane, generating toxic oxygen species, and damaging mitochondria — making resistance much harder to develop.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05308APA
Chang, Che-Kang; Kao, Mou-Chieh; Lan, Chung-Yu. (2021). Antimicrobial Activity of the Peptide LfcinB15 against Candida albicans.. Journal of fungi (Basel, Switzerland), 7(7). https://doi.org/10.3390/jof7070519
MLA
Chang, Che-Kang, et al. "Antimicrobial Activity of the Peptide LfcinB15 against Candida albicans.." Journal of fungi (Basel, 2021. https://doi.org/10.3390/jof7070519
RethinkPeptides
RethinkPeptides Research Database. "Antimicrobial Activity of the Peptide LfcinB15 against Candi..." RPEP-05308. Retrieved from https://rethinkpeptides.com/research/chang-2021-antimicrobial-activity-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.